Valuable Role of Fluorodeoxyglucose-PET in Therapeutic Decision Making and Theranostics of Neurologic Disorders in Conjunction with Non-Fluorodeoxyglucose Tracers.
文献摘要
Brain ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is an important functional imaging modality for evaluating glucose metabolism. Over time, it has been observed that various metabolic patterns can support diagnoses, inform prognosis, guide therapeutic decision-making, and assess treatment response. Clinical applications span seizures, brain tumors, traumatic brain injury, neuroinflammatory and infectious disorders, neurodegenerative diseases, and other chronic neurological conditions. Although FDG is not itself a theranostic radiopharmaceutical, its ability to characterize metabolism may contribute to treatment planning, particularly in molecularly targeted neuro-oncology. This chapter reviews established and investigational applications of brain FDG-PET, emphasizing disease characterization, therapeutic selection, and response assessment.